in this issue:
Lenalidomide for relapsed MM with severe renal impairment
Carfilzomib-based therapy for MM in the real world
VTD superior to VCD prior to intensive therapy in MM
Treating MM with high-risk cytogenetics
Pomalidomide/ cyclophosphamide/ dexamethasone in relapsed MM
Single vs. tandem highdose melphalan, then autologous SCT, in MM
Daratumumab monotherapy in heavily pretreated, relapsed/refractory MM
Please login below to download this issue (PDF)